Ranbaxy Signs Agreement With Validus

Ranbaxy Pharmaceuticals (RPI), a wholly owned subsidiary of Ranbaxy has entered into an agreement with Validus Pharmaceuticals (Validus) to market and distribute an authorized generic version of Rocaltrol (calcitriol) in both softgel capsules and an oral liquid formulation.

Rocaltrol is indicated in the management of secondary hyperparathyroidism and resultant metabolic bone disease in patients with moderate to severe chronic renal failure not yet on dialysis, and in the management of hypocalcemia and the resultant metabolic bone disease in patients undergoing chronic renal dialysis.

Rocaltrol is also indicated in the management of hypocalcemia and its clinical manifestations in patients with postsurgical hypoparathyroidism, idiopathic hypoparathyroidism, and pseudohypo-parathyroidism.

The company will launch product immediately to all classes of trade in the US market, and expects to be the only generic company offering all forms and strengths of generic Rocaltrol.

Jim Meehan, vice president of sales and distribution at RPI, said: Ranbaxy was very pleased to be selected by Validus as their distribution partner for an authorized generic version of Rocaltrol. This product represents commercial opportunity for Ranbaxy which will increase our visibility and presence in the US healthcare system. We look forward to a long and prosperous partnership with Validus.